Combinations of mRNAs encoding immune modulating polypeptides and uses thereof

Patent metadata

Field	Value
Publication number	US-10285950-B2
Application number	US-201816227810-A
Country	US
Kind code	B2
Filing date	Dec 20, 2018
Priority date	May 18, 2016
Publication date	May 14, 2019
Grant date	May 14, 2019

Abstract

The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).

First claim

What is claimed is:

1. A method for treating cancer in a subject by activating T cells in vivo, comprising administering to the subject
(i) a first messenger RNA (mRNA) comprising an open reading frame (ORF) encoding a human IL-23 polypeptide;
(ii) a second mRNA comprising an ORF encoding a human IL-36gamma polypeptide; and
(iii) a third mRNA comprising an ORF encoding a human OX40L polypeptide, thereby activating T cells in vivo to treat cancer in the subject.

2. The method of claim 1 , wherein activating T cells results in one or more of: a reduction or a decrease in the size of a tumor, inhibition of growth of a tumor, and induction of a memory T cell response.

3. The method of claim 1 , wherein the human IL-23 polypeptide comprises an IL-12p40 polypeptide operably linked, with or without a linker, to an IL-23p19 polypeptide.

4. The method of claim 3 , wherein the human IL-23 polypeptide comprises an IL-12p40 polypeptide operably linked via a linker to an IL-23p19 polypeptide, and wherein the linker is a Gly/Ser linker.

5. The method of claim 1 , wherein the human IL-23 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 140, wherein the human IL-36gamma polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 16, and wherein the human OX40L polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 21.

6. The method of claim 5 , wherein
(i) the first mRNA comprises an ORF comprising a nucleotide sequence at least 90% identical to the nucleotide sequence as set forth in SEQ ID NO: 141;
(ii) the second mRNA comprises an ORF comprising a nucleotide sequence at least 90% identical to the nucleotide sequence as set forth in SEQ ID NO: 143; and
(iii) the third mRNA comprises an ORF comprising a nucleotide sequence at least 90% identical to the nucleotide sequence as set forth in SEQ ID NO: 145.

7. A method for treating cancer in a subject by activating T cells in vivo, comprising administering to the subject
(i) a first mRNA encoding a human IL-23 polypeptide, wherein the first mRNA comprises an ORF comprising a nucleotide sequence at least 90% identical to the nucleotide sequence as set forth in SEQ ID NO: 141 or comprises the nucleotide sequence as set forth in SEQ ID NO: 141;
(ii) a second mRNA encoding a human IL-36gamma polypeptide, wherein the second mRNA comprises an ORF comprising a nucleotide sequence at least 90% identical to the nucleotide sequence as set forth in SEQ ID NO: 143 or comprises the nucleotide sequence as set forth in SEQ ID NO: 143; and
(iii) a third mRNA encoding a human OX40L polypeptide, wherein the third mRNA comprises an ORF comprising a nucleotide sequence at least 90% identical to the nucleotide sequence as set forth in SEQ ID NO: 145, or comprises the nucleotide sequence as set forth in SEQ ID NO: 145,
thereby activating T cells in vivo to treat cancer in the subject.

8. The method of claim 7 , wherein
(i) the first mRNA comprises an ORF comprising the nucleotide sequence as set forth in SEQ ID NO: 141;
(ii) the second mRNA comprises an ORF comprising the nucleotide sequence as set forth in SEQ ID NO: 143; and
(iii) the third mRNA comprises an ORF comprising the nucleotide sequence as set forth in SEQ ID NO: 145.

9. The method of claim 8 , wherein activating T cells results in one or more of: a reduction or a decrease in the size of a tumor, inhibition of growth of a tumor, and induction of a memory T cell response.

10. The method of claim 7 , wherein the first mRNA, second mRNA and third mRNA each comprise a 5′ untranslated region (UTR) comprising the nucleotide sequence as set forth in SEQ ID NO: 27, and a 3′ UTR comprising the nucleotide sequence as set forth in SEQ ID NO: 120.

11. The method of claim 10 , wherein the first, second and third mRNAs are each fully modified with chemically-modified uridines.

12. The method of claim 11 , wherein the chemically modified uridines are N1-methylpseudouridines.

13. The method of claim 7 , wherein the first, second and third mRNAs are formulated in the same lipid nanoparticle.

14. The method of claim 13 , wherein the first, second and third mRNAs are formulated in the lipid nanoparticle at a mass ratio of OX40L:IL-23:IL-36gamma of 1:1:2.

15. A method for treating cancer in a subject by activating T cells in vivo, comprising administering to the subject
(i) a first mRNA encoding a human IL-23 polypeptide, wherein the first mRNA comprises a nucleotide sequence at least 90% identical to the nucleotide sequence set forth in SEQ ID NO: 142 or comprises the nucleotide sequence set forth in SEQ ID NO: 142;
(ii) a second mRNA encoding a human IL-36gamma polypeptide, wherein the second mRNA comprises a nucleotide sequence at least 90% identical to the nucleotide sequence set forth in SEQ ID NO: 144 or comprises the nucleotide sequence set forth in SEQ ID NO: 144; and
(iii) a third mRNA encoding a human OX40L polypeptide, wherein the third mRNA comprises a nucleotide sequence at least 90% identical to the nucleotide sequence set forth in SEQ ID NO: 146 or comprises the nucleotide sequence set forth in SEQ ID NO: 146,
thereby activating T cells in vivo to treat cancer in the subject.

16. The method of claim 15 , wherein
(i) the first mRNA comprises the nucleotide sequence set forth in SEQ ID NO: 142;
(ii) the second mRNA comprises the nucleotide sequence set forth in SEQ ID NO: 144; and
(iii) the third mRNA comprises the nucleotide sequence set forth in SEQ ID NO: 146.

17. The method of claim 16 , wherein activating T cells results in one or more of: reduction or decrease in the size of a tumor, inhibition of growth of a tumor, and induction of a memory T cell response.

18. The method of claim 15 , wherein the first, second and third mRNAs are fully modified with N1-methylpseudouridine.

19. The method of claim 15 , wherein the first, second and third mRNAs are formulated in the same lipid nanoparticle.

20. The method of claim 19 , wherein the first, second and third mRNAs are formulated in the lipid nanoparticle at a mass ratio of OX40L:IL-23:IL-36gamma of 1:1:2.

Assignees

• Modernatx Inc

Inventors

• Frederick Joshua
• Bai Ailin
• Presnyak Vladimir
• Hoge Stephen
• Benenato Kerry
• Mcfadyen Iain
• Kumarasinghe Ellalahewage Sathyajith
• Hewitt Susannah

Classifications

• A61K2039/505

  comprising antibodies · CPC title

• C07K14/5443

  IL-15 · CPC title

• A61K2039/54

  characterised by the route of administration · CPC title

• A61K38/20 Primary

  Interleukins [IL] · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title